Inovio Pharmaceuticals, Inc. (NASDAQ:INO) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 8,603,835 shares, a decline of 20.5% from the July 14th total of 10,821,529 shares. Approximately 10.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,606,177 shares, the short-interest ratio is presently 2.4 days.
Shares of Inovio Pharmaceuticals (INO) opened at 5.52 on Thursday. The stock’s market cap is $498.05 million. The stock’s 50 day moving average is $6.59 and its 200 day moving average is $6.80. Inovio Pharmaceuticals has a 52-week low of $5.32 and a 52-week high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The business had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The company’s quarterly revenue was up 229.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.26) earnings per share. On average, equities analysts expect that Inovio Pharmaceuticals will post ($0.92) earnings per share for the current fiscal year.
In related news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the sale, the director now directly owns 740,956 shares in the company, valued at approximately $5,927,648. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 10.60% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. BlueCrest Capital Management Ltd purchased a new position in shares of Inovio Pharmaceuticals during the second quarter valued at about $107,000. PNC Financial Services Group Inc. increased its position in shares of Inovio Pharmaceuticals by 5.0% in the second quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 1,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Inovio Pharmaceuticals during the second quarter valued at about $171,000. Bank of America Corp DE increased its position in shares of Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 3,605 shares during the last quarter. Finally, OxFORD Asset Management LLP purchased a new position in shares of Inovio Pharmaceuticals during the second quarter valued at about $194,000. 22.96% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on INO shares. Nomura reissued a “buy” rating and issued a $40.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 7th. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a research note on Tuesday, July 11th. Finally, Jefferies Group LLC reissued a “neutral” rating and issued a $38.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $20.78.
WARNING: “Inovio Pharmaceuticals, Inc. (INO) Sees Significant Drop in Short Interest” was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2017/08/17/inovio-pharmaceuticals-inc-ino-sees-significant-drop-in-short-interest.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
What are top analysts saying about Inovio Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Inovio Pharmaceuticals Inc. and related companies.